Drug Profile
RFI 641
Latest Information Update: 21 Mar 2002
Price :
$50
*
At a glance
- Originator Wyeth
- Class Antivirals; Triazines
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 21 Mar 2002 Discontinued - Clinical-Phase-Unknown for Respiratory syncytial virus infections in USA (unspecified route)
- 23 Feb 2001 A preclinical study has been added to the Viral Infections pharmacodynamics section
- 12 Oct 2000 A preclinical study has been added to the adverse events and Viral infections antimicrobial activity sections